Fumito Ito MD PhD, FACS
Breast, Melanoma, Surgical Oncology (Other than Breast)
Surgical Oncologist, University of Southern California
Join to View Full Profile
1450 Biggy St.Los Angeles, CA 90033
Dr. Ito is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ito is an Associate Professor in the Department of Surgery at the Keck Medicine of USC, and serves as a Co-Leader of the Translational and Clinical Sciences (TACS) Research Program in the Norris Comprehensive Cancer Center.
Clinical Expertise
- Melanoma and cutaneous malignancies, Breast cancer, Breast surgery, Surgical oncology (non-breast)
Certifications & Licensure
NY State Medical License 2008 - 2027
CA State Medical License 2021 - 2025
MI State Medical License 2010 - 2017
WI State Medical License 2007 - 2011
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
Publications & Presentations
PubMed
- Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient du...Ryutaro Kajihara, Mark D Long, Toshifumi Hoki, Hongbin Chen, Takayoshi Yamauchi
Journal for Immunotherapy of Cancer. 2025-01-25 - Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24 - 3 citationsGeneration, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.Hirohito Ishigaki, Takayoshi Yamauchi, Mark D Long, Toshifumi Hoki, Yuta Yamamoto
Cancer Research Communications. 2024-07-01
Press Mentions
USC Team IDs Biomarker for NSCLC Response to ChemoimmunotherapyMay 17th, 2023- Study Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
- USC Research Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
- Join now to see all
Grant Support
- Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssaySTATE UNIVERSITY OF NEW YORK AT BUFFALO2022–2027
- In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumorsUNIVERSITY OF SOUTHERN CALIFORNIA2021–2026
- USC Stimulating Access to Research in Residency (USC-StARR) ProgramUNIVERSITY OF SOUTHERN CALIFORNIA2021–2025
Committees
- Co-Leader, USC Translational and Clinical Sciences (TACS) program
Other Languages
- Japanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
